Stockscreener 앱 받기
163.17
0.45%
-0.73
시장 영업 전:
164.02
0.85
+0.52%
전일 마감가:
$163.90
열려 있는:
$163.06
하루 거래량:
770.77K
Relative Volume:
0.63
시가총액:
$9.20B
수익:
$763.34M
순이익/손실:
$51.40M
주가수익비율:
179.62
EPS:
0.9084
순현금흐름:
$104.46M
1주 성능:
+10.95%
1개월 성능:
+13.12%
6개월 성능:
+14.06%
1년 성능:
+46.43%
1일 변동 폭
$160.99
$166.43
1주일 범위
$142.29
$166.43
52주 변동 폭
$100.99
$175.77
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
163.17 | 7.39B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
393.38 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
179.63 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
73.63 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
220.05 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.81 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Repligen Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript - AlphaStreet
Is Repligen Corp (RGEN) Undervalued After Q2 Earnings Beat? EPS - GuruFocus
Repligen raises FY2026 adj EPS guidance to $2.03-$2.09 - scanx.trade
Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance - TradingView
Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance - Quiver Quantitative
Repligen: Q2 Earnings Snapshot - Yahoo Finance
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen Corp (RGEN) Institutional Confidence - TradingKey
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen Corp (RGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
Repligen Corp (RGEN) Cash Flow - TradingKey
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corp (RGEN) Income Statement - TradingKey
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RGEN|Repligen Corp|Price:130.800|Chg%:-1.160 - TradingKey
RGEN|Repligen Corp|Price:130.951|Chg%:-1.009 - TradingKey
Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story! - Smartkarma
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Daily Brief Health Care: Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Akeso, Mitesco Inc, Nagaileben, Repligen Corp, Scribe Therapeutics, Cosmos Health and more - Smartkarma
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan
Repligen Corp (RGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research
Canaccord reiterates Hold on Repligen stock after BioLife deal By Investing.com - Investing.com India
RGEN stock holds steady as Repligen backs 2026 growth - Ad-hoc-news.de
Canaccord reiterates Hold on Repligen stock after BioLife deal - Investing.com
Bothell firm fetches $1.5 billion in acquisition by Massachusetts company - The Business Journals
Repligen to Acquire BioLife Solutions for $1.5 Billion, Expanding Leadership in Cell Therapy Market - Minichart
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal - Stock Titan
Repligen to Acquire BioLife Solutions for $11.25 per Share Plus Stock, Enhancing Cell Processing Capabilities - Kalkine Media
US759916AC3 Bond Profile — Key Metrics - TradingView
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach - Yahoo Finance
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal, Expanding Into Cell Therapy - finance.biggo.com
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal - Kalkine Media
Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share - Kalkine Media
What's Going on With Repligen Stock Wednesday?Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
Repligen Corp: If Deal Terminated Under Some - Moomoo
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.37%
0.55%
자본화:
|
볼륨(24시간):